2) BIOPROTO
Abstract
BIOPROTO supports early-phase clinical development and supporting non-clinical safety, tolerability and toxicity data for candidate vaccines and therapeutic drugs prior to transition to System Development & Demonstration. This work provides safe and effective medical defense against validated biological threat agents and emerging infectious disease biothreats including bacteria, toxins, and viruses. This work also involves the evaluation of Food and Drug Administration (FDA)-approved therapeutics for operational use, as well as generation of novel drug products and formulations, to enhance level of protection and/or operational utility for the Warfighter. This effort reduces programmatic risk of failure in the advanced development phase.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2024
- Source ID
- 3601f0ac77234f5a14a0553e530fd123